secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ensysce Biosciences, Inc. (ENSC)
CIK:        0001716947
Form:       8-K
Filed at:   2026-09-29T12:31:00+00:00
Accession:  0001493152-26-044802
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.03, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Ensysce Biosciences amends Series C preferred certificate to remove holder cash redemption provision
--------------------------------------------------------------------------------

- On September 25, 2026, Ensysce Biosciences amended the Series C Certificate of Designation to remove Section 6.5.3 and related references.
- Section 6.5.3 had allowed holders to redeem Series C Preferred for cash after stockholder approval of conversion if Common Stock delivery failed, at then-current fair value.
- The amendment was effective upon filing; a Certificate of Correction had been filed on August 6, 2026 after the original August 5, 2026 Series C designation.
- Ensysce filed the amendment as Exhibit 3, and CEO Lynn Kirkpatrick signed the report on September 29, 2026.
- The Series C Preferred Stock and Common Stock each have par value $0.0001 per share; Common Stock trades as ENSC on Nasdaq.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226044802/0001493152-26-044802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716947/000149315226044802/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-044802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer